Esophageal cancer
Conditions
Interventions
Observation Group of Immune cross-line therapy:None
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Only patients who meet all of the following inclusion criteria and do not meet any of the exclusion criteria can be enrolled in this study: (1) Patients diagnosed with esophageal squamous cell carcinoma by pathology or clinical diagnosis; (2) Patients who have received immune checkpoint inhibitors during first-line and second-line treatments; (3) Patients aged 18 or above; (4) Patients with complete medical record data and follow-up information;
Exclusion criteria
Exclusion criteria: (1) Patients with missing data and information related to key research; (2) Patients with the second primary cancer;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Second-line progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| First-line progression-free survival; 1-year PFS1 rate; 1-year PFS2 rate;Objective response rate;Disease control rate;Duration of relief;Overall survival;The total number of inpatient days; | — |
Countries
China
Contacts
Public ContactDao Xin
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed